DNTH- Dianthus Therapeutics, Inc.

Name: Dianthus Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Dianthus Therapeutics, Inc. (DNTH) has 5 insiders with recent SEC Form 4 filings, including 1 buy and 9 sells. DNTH is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
CFO	Savitz Ryan	89.7K	$7.40M	-
Other	Carr Edward	16.2K	$1.33M	-
VP	Randhawa Simrat	8.0K	$659.8K	-26,530
Dir	Soteropoulos Paula	0	-	-
CEO	Garcia Marino	0	-	-

Activity

Buys and sells only

Transactions

10 filings · page 3

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Sep 16, 2021	Nichols David Wayne	Chief Technical Officer	Sell	5,694	$6.73	$38,320.62	-28.5%	-27.5%	-75.5%
Sep 16, 2021	Beetham Thomas W.	See Remarks	Sell	6,103	$6.73	$41,073.19	-30.5%	-27.5%	-75.5%
Jun 29, 2020	Booth Bruce70	Director	Buy	1,250,000	$8.00	$10,000,000.00	New	-	-
Jan 10, 2020	Gardner Jason	See Remarks	Sell	11,200	$15.25	$170,800.00	-4.3%	-	-
Jan 2, 2020	Davis John C. Jr	Chief Medical Officer	Sale+OE	11,294	$15.04	$169,816.58	-57.6%	-	-
Jan 2, 2020	Gardner Jason	See Remarks	Sell	2,800	$15.10	$42,280.00	-1.1%	-	-
Dec 24, 2019	Isacson Christina K.	Chief Business Officer	Sell	4,463	$16.01	$71,452.63	-5.1%	-	-
Dec 24, 2019	Zdraveski Zoran	See Remarks	Sell	7,902	$16.00	$126,432.00	-5.8%	-	-
Dec 23, 2019	Zdraveski Zoran	See Remarks	Sell	4,181	$16.03	$67,021.43	-3.0%	-	-
Dec 23, 2019	Isacson Christina K.	Chief Business Officer	Sell	9,867	$16.03	$158,168.01	-10.1%	-	-

← PrevPage 3Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC